Gilli F - Search Results

1

Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.

Gilli F, Valentino P, Caldano M, Granieri L, Capobianco M, Malucchi S, Sala A, Marnetto F, Bertolotto A. Gilli F, et al. Neurology. 2008 Dec 9;71(24):1940-7. doi: 10.1212/01.wnl.0000327340.50284.8d. Epub 2008 Oct 29. Neurology. 2008. PMID: 18971450

2

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D. Gilli F, et al. Brain. 2004 Feb;127(Pt 2):259-68. doi: 10.1093/brain/awh028. Epub 2003 Nov 7. Brain. 2004. PMID: 14607790

3

Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.

Gilli F, Marnetto F, Stefanuto G, Rinaldi V, Farinazzo F, Malucchi S, Capobianco M, Caldano M, Sala A, Bertolotto A. Gilli F, et al. Mol Diagn. 2004;8(3):185-94. doi: 10.1007/BF03260063. Mol Diagn. 2004. PMID: 15771557

4

Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.

Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, Di Sapio A, Capobianco M, Sala A, Malucchi S, Kappos L, Lindberg RL, Bertolotto A. Gilli F, et al. J Neuroimmunol. 2007 Dec;192(1-2):198-205. doi: 10.1016/j.jneuroim.2007.09.025. Epub 2007 Oct 22. J Neuroimmunol. 2007. PMID: 17950468 Clinical Trial.

5

Interferon-beta responders and non-responders. A biological approach.

Bertolotto A, Gilli F. Bertolotto A, et al. Among authors: gilli f. Neurol Sci. 2008 Sep;29 Suppl 2:S216-7. doi: 10.1007/s10072-008-0941-2. Neurol Sci. 2008. PMID: 18690496 Review.

6

One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.

Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, Granieri L, Bertolotto A. Malucchi S, et al. Among authors: gilli f. J Neurol. 2011 May;258(5):895-903. doi: 10.1007/s00415-010-5844-5. Epub 2010 Dec 12. J Neurol. 2011. PMID: 21153733 Clinical Trial.

7

Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis.

Gilli F, Navone ND, Perga S, Marnetto F, Caldano M, Capobianco M, Pulizzi A, Malucchi S, Bertolotto A. Gilli F, et al. Arch Neurol. 2011 Jul;68(7):879-88. doi: 10.1001/archneurol.2011.32. Epub 2011 Mar 14. Arch Neurol. 2011. PMID: 21403007

8

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT. Bertolotto A, et al. Among authors: gilli f. J Immunol Methods. 2001 Oct 1;256(1-2):141-52. doi: 10.1016/s0022-1759(01)00434-3. J Immunol Methods. 2001. PMID: 11516761

9

Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.

Gilli F, Sala A, Bancone C, Salacone P, Gallo M, Gaia E, Bertolotto A. Gilli F, et al. J Immunol Methods. 2002 Apr 1;262(1-2):187-90. doi: 10.1016/s0022-1759(02)00008-x. J Immunol Methods. 2002. PMID: 11983232

10

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT. Bertolotto A, et al. Among authors: gilli f. Neurology. 2003 Feb 25;60(4):634-9. doi: 10.1212/01.wnl.0000046662.03894.c5. Neurology. 2003. PMID: 12601105 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters